Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Key facts
Founded
2025
1 years
Office countries
1
1 address
Company type
Privately Held
self-reported
Description
Overview:
SAL-Check is a pioneering liver health screening and diagnostics solution in development at Griffith University, offering a world-first saliva-based diagnostic for the early detection of liver fibrosis. As liver disease continues to rise silently in millions worldwide, SAL-Check aims to fill a critical gap by delivering non-invasive, low-cost, and accessible screening — without the need for blood draws or specialist imaging.
Technology Origin:
Developed within a multidisciplinary research team led by Prof. Chamindie Punyadeera, SAL-Check is backed by world-class expertise in salivary diagnostics, with clinical partnerships and extensive validation work underway. The project has received significant competitive grant funding and is being translated through Griffith University’s research and commercialisation pipeline.
Current Status:
This is currently an active research and commercialisation project at Griffith University, progressing toward prototype development and clinical validation. SAL-Check has already generated early industry interest through global EOIs and partner engagement. Through the LuminaX accelerator program, we are testing the feasibility of establishing SAL-Check as a spinout company.
Spinout Model:
Subject to investor funding and licensing agreements with Griffith University, the project is intended to be spun out into a dedicated diagnostics company. The spinout will serve as a platform for saliva-based health diagnostics, with SAL-Check as its lead product targeting general population screening and specialist clinical pathways for liver disease.
We're currently seeking:
- Seed investors aligned with healthtech/medtech
- Strategic partners in diagnostics, pharmacy, and corporate health
- Expressions of interest from collaborators and co-development partners
Specialties
All 10 specialties
- Saliva Diagnostics
- Liver Health Screening
- Point of Care Diagnostics
- Novel Biomarkers
- Clinical Validation
- Medical Device
- Non-Invasive Testing
- Rapid Antigen Test (RAT)
- Platform Technologies in Diagnostics
- Rural and Remote Diagnostics
Locations
Country footprint
Show as table · Offices in 1 country
| Countries | 1 |
|---|---|
| Primary country | AU |
All codes: AU
Addresses
- AUInstitute for Biomedicine and Glycomics (IBG), Griffith University; N75, 170 Kessels Rd, Nathan; Brisbane, Queensland 4111Primary
Grid intelligence Members
Signals & hiring
Hiring, headcount and registry-change signals, streamed to members.
Latest signal
Hiring activity
Headcount trend
Financials
Registry-filed capital and financial indicators, standardised by TheGrid.
Paid-up capital
Fiscal period
Registered charges
Revenue
Profit / loss
FAQ
Where does SAL-Check have offices?
One address on record, Australia only. Primary: Institute for Biomedicine and Glycomics (IBG), Griffith University, N75, 170 Kessels Rd, Nathan, Brisbane, Queensland 4111.
What does SAL-Check list as its specialties?
Ten tags on the brand's own list, among them medical device.
Which companies are listed alongside SAL-Check?
4 profiles list SAL-Check as a peer — 56th percentile in Biotechnology Research. It lists ten peers of its own. Celium Technologies and gutgutgoose list it back.